Skip to main content
MedPathMedPath Home
Clinical Trials/NCT04460599
NCT04460599
Unknown
Not Applicable

Description of neurolOgical Involvement Observed During SARS COV2 Infection

Centre d'Investigation Clinique et Technologique 8051 site in 1 country30 target enrollmentMarch 8, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsEncephalitis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Encephalitis
Sponsor
Centre d'Investigation Clinique et Technologique 805
Enrollment
30
Locations
1
Primary Endpoint
Primary
Last Updated
5 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

Description of the neurological impairment: clinico-radiological and electrophysilogical correlations

Detailed Description

Describe short and long term clinical radiological and electrophysilogical presentations of neurological damage central and peripheral SARS COV2 infection Describe the association between neurological, respiratory and dysautonomic Determine the prognosis of neurological damages to short and long term.

Registry
clinicaltrials.gov
Start Date
March 8, 2020
End Date
September 30, 2020
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Centre d'Investigation Clinique et Technologique 805
Responsible Party
Principal Investigator
Principal Investigator

david orlikowski

Professor

Centre d'Investigation Clinique et Technologique 805

Eligibility Criteria

Inclusion Criteria

  • •PCR SARS COV2 positive or CT Scan
  • •Central neurological signs such as confusion, epilepsy, abnormal movement, pyramidal signs, motor or sensory deficit, involvement of cranial pairs (such as anomie or ageusia) or peripheral.
  • •Dysautonomic signs such as hypotension or hypertension, bradycardia or tachycardia, hypothermia, SIADH not explained by therapy or a pathology other than SARS COV 2 infection

Exclusion Criteria

  • •Contraindication to performing an MRI scan
  • •Pregnant woman
  • •No follow-up possible at 6 months

Outcomes

Primary Outcomes

Primary

Time Frame: 6 months

incidence of objective neurological damage

Secondary Outcomes

  • Secondary(6 months)

Study Sites (1)

Loading locations...

Similar Trials

Not yet recruiting
Not Applicable
Inflammatory and Degenerative Muscle DiseaseInflammatory Muscle Disease
NCT05738590Assiut University60
Recruiting
Not Applicable
Investigation of neurophysiological marker in internet game addictioMental and behavioral disorders
KCT0001849Seoul Metropolitan Government Seoul National University Boramae Medical Center750
Active, not recruiting
Not Applicable
Clinical and neuropsychological factors associated with second generation antipsychotic response in patients diagnosed with first episode of early onset schizophrenia spectrum disordersFirst episode of early onset schizophrenia spectrum disordersMedDRA version: 14.1Level: LLTClassification code 10040705Term: Simple schizophreniaSystem Organ Class: 10037175 - Psychiatric disordersTherapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
EUCTR2009-017024-82-ESFUNDACIÓN SANT JOAN DE DE
Recruiting
Not Applicable
Pathophysiological analysis of neurosurgical diseases by using upright-position computed tomographyeurosurgical diseases(chronic subdural hematoma, brain tumor, hydrocephalus, cerebrospinal fluid hypovolemia, Chiari malformation, skull defect)
JPRN-UMIN000033000Keio University School of Medicine100
Recruiting
Not Applicable
Pathophysiology underlying neuronal information processing in ADHDF90Hyperkinetic disorders
DRKS00016580Klinik für Psychiatrie und Psychotherapie der Uniklinik Köln37